Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bifidobacterium animalis subsp lactis HN019
- Development stage
- Phase 2
- Lead developer
- Fonterra
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Bifidobacterium animalis subsp lactis HN019 is a specific probiotic bacterial strain used as an orally administered live microbe for gastrointestinal and broader health applications. It has been studied clinically in functional constipation and has also been reported in human studies of metabolic syndrome and in allergy prevention research. Its therapeutic rationale is microbiome modulation rather than single-receptor pharmacology: after oral administration, the strain is intended to transiently interact with the gut ecosystem and host mucosal immune system, with proposed effects on intestinal transit, stool patterns, epithelial barrier function, and inflammatory signaling. Publicly verifiable evidence includes a registered ChiCTR randomized placebo-controlled trial in functional constipation and peer-reviewed publications involving this exact strain. The strain has been associated in different studies with effects on bowel function, inflammatory cytokines, lipids, and other host-response measures, but it is best characterized as a strain-specific probiotic live biotherapeutic or nutraceutical-type product rather than a conventional pharmaceutical small molecule.
- Brand names
- SureStart BifidoB HN019
- Other names
- Bifidobacterium lactis HN019B. lactis HN019Bifidobacterium animalis subsp lactis HN019
02
Targets
Intestinal epithelial cell surface glycoconjugates
Beyond the preview
Go deeper on bifidobacterium animalis subsp lactis HN019.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bifidobacterium animalis subsp lactis HN019.